InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（0 笔）
内部人交易记录
董事已披露买入
0
已披露卖出
0
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
无可用的信号评分。
Discover the full record of transactions filed by Mammen Mathai, 董事. Insider active across 2 companies, notably 10x Genomics, Inc.. Aggregated, 7 filings have been published. History available since 11 June 2021. The latest transaction was filed on 11 June 2024 (Attribution). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Mammen Mathai
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报7 总计
8,649 股0Class A Common StockSEC:0001610717-24-000326:0
1,865 股0Class A Common StockSEC:0001610717-23-000173:0
200,000 股@ US$1.16100.0% 占其流量Class A Common StockSEC:0001610717-23-000035:0
2,120 股0Class A Common StockSEC:0001567619-22-013119:0
7,740 股0Common StockSEC:0001225208-22-002372:0
7,418 股0Common StockSEC:0001225208-22-002220:0
625 股0Class A Common StockSEC:0001209191-21-040689:0
7 条申报中的 7 条
About Mammen Mathai
Mathai Mammen is a Board Member and Executive Vice President of Pharmaceuticals and R&D at 10x Genomics, Inc. and JOHNSON & JOHNSON. He plays an essential role in the research and innovation strategy of these companies.
